Description

Glimepiride Voglibose and Metformin Hydrochloride Tablets are used to treat the Type 2 Diabetes M and also useful to reduce the glucose levels in adults GLIMITERIS MV1 0.2 is a triple-drug combination therapy formulated for the management of type 2 diabetes mellitus (T2DM). It integrates three complementary antidiabetic agents—Glimepiride, Voglibose, and Metformin Hydrochloride (SR)—to provide effective glycemic control in patients who require more than monotherapy or dual therapy to manage blood glucose levels. Mechanism of Action: Each component of GLIMITERIS MV1 0.2 works through a distinct mechanism: Glimepiride (1 mg) – A Sulfonylurea: Stimulates pancreatic beta cells to increase insulin secretion. Has a long duration of action with a lower risk of hypoglycemia compared to older sulfonylureas. Voglibose (0.2 mg) – An Alpha-Glucosidase Inhibitor: Delays the digestion and absorption of carbohydrates in the intestine. Reduces postprandial blood glucose (PPBG) spikes without causing hypoglycemia. Works locally in the gut and is minimally absorbed systemically. Metformin HCl (500 mg SR) – A Biguanide: Decreases hepatic glucose production (gluconeogenesis). Enhances insulin sensitivity and peripheral glucose uptake. Does not cause hypoglycemia and may assist with modest weight reduction. The sustained-release (SR) formulation improves gastrointestinal tolerability and provides longer glycemic control. Indications: GLIMITERIS MV1 0.2 is indicated for: Type 2 Diabetes Mellitus in adults As an adjunct to diet and exercise to improve glycemic control In patients inadequately controlled on monotherapy or dual therapy For better postprandial and fasting blood sugar regulation Key Benefits: ✅ Comprehensive Glycemic Control: Targets fasting, postprandial, and overall glucose levels. ✅ Reduced Pill Burden: One tablet combines three mechanisms of action. ✅ Postprandial Spike Management: Voglibose effectively blunts carbohydrate-induced spikes. ✅ Lower Hypoglycemia Risk: Metformin and voglibose components do not cause hypoglycemia. ✅ Weight Neutral to Weight-Loss Friendly: Metformin may help prevent weight gain associated with sulfonylureas. ✅ Gastrointestinal Tolerability: SR formulation of metformin enhances GI tolerability. Dosage and Administration: Recommended Dose: One tablet, orally, once or twice daily, with meals or as directed by the physician. Administration Guidelines: Take with the first bite of a main meal to optimize the effect of voglibose and reduce gastrointestinal discomfort. Swallow the tablet whole with water. Do not crush or chew the SR formulation. Dose Adjustments: Dosage should be individualized based on the patient's clinical response, renal function, and blood glucose monitoring. Contraindications: GLIMITERIS MV1 0.2 is contraindicated in patients with: Hypersensitivity to any of the components (Glimepiride, Voglibose, or Metformin) Type 1 diabetes mellitus or diabetic ketoacidosis Severe renal impairment (eGFR <30 mL/min/1.73 m²) Hepatic dysfunction Severe gastrointestinal disorders History of lactic acidosis Pregnant or lactating women (unless specifically advised by a physician) Warnings and Precautions: Hypoglycemia Risk: Increased when combined with other antidiabetic agents or in patients with irregular meals. Lactic Acidosis: A rare but serious side effect of metformin; monitor renal function periodically. Renal Monitoring: Metformin should be used cautiously in patients with mild-to-moderate renal dysfunction. GI Tolerance: Voglibose and metformin may cause flatulence, bloating, or mild diarrhea—usually self-limiting. Liver Function Tests: Periodic monitoring recommended. Vitamin B12 Deficiency: Long-term metformin use may reduce B12 absorption—monitor in long-term therapy. Adverse Effects: Common Side Effects: Glimepiride: Hypoglycemia, dizziness, weight gain Voglibose: Flatulence, abdominal discomfort, diarrhea Metformin SR: Nausea, bloating, mild diarrhea, metallic taste Rare but Serious: Lactic acidosis (from metformin) Allergic reactions (rash, itching, swelling) Hepatic enzyme elevation Severe hypoglycemia (especially with missed meals or overdosing) Seek immediate medical attention in case of symptoms like muscle pain, rapid breathing, confusion, or unusual tiredness. Drug Interactions: Increased Hypoglycemia Risk: With insulin, beta-blockers, or other sulfonylureas Reduced Metformin Effectiveness: With corticosteroids, diuretics, and estrogens Risk of Lactic Acidosis: Alcohol and contrast media with metformin Always inform your healthcare provider of all medications, supplements, or herbal products being taken. Storage: Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children.